the changing patterns of these infections are urgently needed. A recent article summarizing the discussion of a round table meeting organized by the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) highlighted list priorities in the management of MDR pathogens, identified areas that urgently require more research and made recommendations that should be implemented today [3] . Ideal antibiotic utilization is an area of uncertainty requiring additional investigations aimed at better understanding dose optimization, duration of therapy, use of combination treatment, aerosolized antibiotics and the integration of rapid diagnostics as a guide for treatment [4] . Recent advancements in laboratory techniques allow for the rapid identification of the infecting pathogen and antibiotic susceptibility testing that may guide fine-tuning of empirically selected regimens, facilitate de-escalation of unnecessary antimicrobials and support infection control decisions [5] . To combat the issue of escalating antimicrobial resistance and IEAT, combination antimicrobial regimens have become increasing recommended for empiric and definitive therapy, especially for carbapenemase-producing K. pneumoniae [6] . There is also moderate to limited evidence in support of combination therapy for treating carbapenemase-producing A. baumannii infections, including pneumonia and bacteraemia [7] . One major issue in the spread of Gram-negative MDR bacteria is the overuse of carbapenems for empirical therapy that creates selective pressure for development of carbapenem resistance. Recently there has been a reappraisal of old compounds and a number of new drugs that will be important in the treatment of selected MDR pathogens and allow intensivists the possibility for "sparing" carbapenems. By definition, extended spectrum β-lactamases [8] .
Moreover, the presence of severe influenza continues to result in appreciable mortality especially among patients with compromised cardiopulmonary status and has been reported as a risk factor for invasive pulmonary aspergillosis and secondary bacterial infection with MDR pathogens even in non-immunocompromised patients [1] .
Catheter and device-related infections represent a significant part of hospital-acquired infections, mostly due to the formation of biofilms. Hand hygiene and skin antisepsis for catheter insertion and handling remain the milestones of prevention of catheter colonisation [9] . Superiority of skin disinfection with chlorhexidine-alcohol was further potentiated with a new randomised controlled trial in 16 intensive care units, from Japan [10] . In the latter, both 0.5% and 1.0% alcohol chlorhexidine gluconate were superior to 10% aqueous povidone iodine for the prevention of intravascular catheter colonisation. In a high volume burn unit in the USA, a sustained reduction of central-line-associated bloodstream infection (CLABSI) rates from 15.5 per 1000 central-line days to zero over 3 years became feasible, with the implementation of a rigorous program translating research into practice including among others chlorhexidine bathing, chlorhexidine dressings and use of alcohol-impregnated caps [11] .
Novel insights into biofilms will in the near future enable targeting of mature biofilms with short-course catheter locks for catheter salvage, with antibiotic adjuvants or enzymes (DispersinB, DNaseI) or cations chelators (EDTA), or molecules that directly target persister cells (sugars, ADEP4, antimicrobial peptides, etc.) [1] . As another glimpse into the future, phage therapy and passive immunization could improve our ability to treat biofilm-forming bacteria [5] . Direct molecular detection of pathogens in blood is anticipated as a breakthrough in microbiological diagnosis of severe infections. A multicentre, open-label, cluster-randomised crossover trial (EVAMICA) showed that the addition of direct molecular detection of pathogens in the blood with a commercial test to standard care improved microbiological diagnosis in patients with severe sepsis and shortened the time to start a species-specific antimicrobial therapy [12] . Finally, therapeutic drug monitoring (TDM) provides a shift to refined dosing strategies for antimicrobials, compared to standard dosing, which is warranted to enhance the probability of achieving adequate drug exposure and clinical success [13] .
Invasive fungal infections (IFIs) are an increasingly frequent cause of severe infections with mortality that ranges between 30% and 40% in episodes occurring in critically ill patients [14] . Approximately 80% of IFIs are due to Candida species that remains the predominant pathogen in ICU. Over the past decades, incidence of invasive candidiasis (IC) has shown progressively increasing or stable rates in most regions [14, 15] , probably as a result of the growing complexity of surgical procedures, the presence of patient populations at higher risk of infection and the changes in patient demographic characteristics [14] . While candidemia episodes are easier to recognize compared to deep-seated candidiasis, current recommendations mainly focus on the management of candidemia, while trials on deep forms such as intra-abdominal candidiasis (IAC) are lacking. Adequate antifungal treatment and source control, i.e. catheter removal during candidemia or abscess drainage in IAC, are independent predictors of reduced mortality [14, 16] . Mortality for IC should also be attributed to suboptimal diagnostic tools. Standard mycological conventional blood culture is a gold standard, but may fail to diagnose IC in up to 25-50%, whereas time to positivity for yeast and species identification can take several days from the time the blood culture is drawn, depending on the implicated Candida species [16] . Unless antifungal therapy is promptly initiated by the confirmation of IC, effective antifungal therapy may be further delayed. In recent years, other non-culture-based tests for diagnosis and susceptibility have been advocated to offset the diagnostic challenges and improve patient management, but their availability is currently limited. BDG (beta-d-glucan) testing has shown high negative predictive value and should be useful to rule out IC; nevertheless, it is not specific for IC as it is considered a pan-fungal diagnostic method. Interestingly BDG showed an important value in differentiating IAC from colonisation in critically ill patients with gastrointestinal abdominal problems [17] . Over the last decade, early antifungal agents have been prescribed in adult patients admitted to the ICU for various purposes corresponding to prophylaxis or pre-emptive or empirical therapies. Various definitions have been proposed for pre-emptive therapy over the last 10 years. Consequently, the concept of pre-emptive strategy has been an area of confusion as treated patients have been described by some authors as having received empirical therapy while others refer to pre-emptive or presumptive therapy. This confusion has lead to overtreatment with the potential detrimental impact of fluconazole on Candida ecology in ICU and/or on Candida susceptibility to antifungal drugs [18] . The ESCMID guidelines no longer consider fluconazole to be the drug of choice for invasive candidiasis, and recommend the use of echinocandins as first-line empirical treatment [14] . The 2016 Infectious Diseases Society of America (IDSA) guidelines also prioritize echinocandins as first-line treatment prior to species identification and susceptibility testing. Favourable characteristics of echinocandins compared with fluconazole include fungicidal activity, broader spectrum of activity, excellent safety profile and few drug-drug interactions. However, despite growing evidence of the superiority of echinocandins and the emergence of resistance to fluconazole, especially among non-albicans strains of Candida, fluconazole is still widely used in clinical practice for the treatment of candidiasis. The optimal duration of intravenous therapy for IC has not been extensively studied. In a recent non-comparative trial, step-down to an oral azole was allowed after 5 days of intravenous treatment [19] . Early de-escalation, however, did not seem to impact survival. Although antimicrobial stewardship programmes are one of the highest priorities in healthcare systems, few refer to the implementation of antifungal stewardship and highlight specific points on which efforts should be focused. The most remarkable rules for developing antifungal stewardship programmes targeting antifungal treatment bundles are reported in Table 1 . Table 1 The 10 most remarkable rules Stop early useless therapy and check duration of therapy (no more than 7-10 days for pre-emptive)
